Atrial fibrillation (AF) is the most common cardiac arrhythmia, causing irregular and often rapid heart rhythms. It accounts for approximately 60 million cases globally, with a rising prevalence due to aging populations and lifestyle factors. Novel therapies are emerging, driven by a growing focus on novel anticoagulants, antiarrhythmic drugs, and gene-based treatments. Recent advancements, including AI-driven drug discovery and personalized medicine, are shaping the market. The atrial fibrillation pipeline analysis by the publisher highlights promising drug candidates in various clinical stages, indicating strong growth potential in the coming years, supported by increasing research investments and regulatory approvals.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to atrial fibrillation.
Atrial fibrillation treatments include anticoagulants to prevent clots, beta-blockers or calcium channel blockers to control heart rate, and antiarrhythmic drugs or procedures like catheter ablation to restore normal rhythm. In November 2024, the U.S. FDA approved AOP Health’s Rapiblyk (landiolol) for atrial fibrillation in critical care settings. Clinical studies confirmed its rapid heart rate control with minimal blood pressure reduction, providing a crucial option for patients requiring immediate intervention.
Potassium channel blockers are emerging as a promising class in the atrial fibrillation pipeline. For instance, AP30663, a KCa2 channel inhibitor, has shown efficacy in animal models. A trial is evaluating its potential in patients with AF episodes lasting seven days or less, comparing intravenous doses of 3 or 5 mg/kg against a placebo.
This product will be delivered within 3-5 business days.
Report Coverage
The Atrial Fibrillation Pipeline Analysis Report by the publisher gives comprehensive insights into atrial fibrillation therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for atrial fibrillation. The atrial fibrillation report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The atrial fibrillation pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with atrial fibrillation treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to atrial fibrillation.
Atrial Fibrillation Pipeline Outlook
Atrial fibrillation (AF) is an irregular and often rapid heart rhythm caused by chaotic electrical signals in the atria, leading to ineffective blood pumping. It can result from high blood pressure, heart disease, or aging. Symptoms include palpitations, fatigue, and shortness of breath. If untreated, AF increases the risk of stroke and heart failure.Atrial fibrillation treatments include anticoagulants to prevent clots, beta-blockers or calcium channel blockers to control heart rate, and antiarrhythmic drugs or procedures like catheter ablation to restore normal rhythm. In November 2024, the U.S. FDA approved AOP Health’s Rapiblyk (landiolol) for atrial fibrillation in critical care settings. Clinical studies confirmed its rapid heart rate control with minimal blood pressure reduction, providing a crucial option for patients requiring immediate intervention.
Atrial Fibrillation Epidemiology
The global prevalence of atrial fibrillation (AF) is estimated to be around 60 million cases, accounting for over 8 million disability-adjusted life years. Studies reveal that from 1990 to 2019, the number of atrial fibrillation and atrial flutter (AF/AFL) cases more than doubled, rising from 28.27 million to 56.67 million. The highest increase occurred in lower-middle-income countries (146.6%) and upper-middle-income countries (145.2%). In low-income countries, prevalence rose by 120.7%. High-income countries experienced a 67.8% increase but still have the highest prevalence at 1,738 cases per 100,000 population.Atrial Fibrillation - Pipeline Therapeutic Assessment
This section of the report covers the analysis of atrial fibrillation drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Small Molecules
- Monoclonal Antibodies
- Anticoagulants
- RNA-Based Therapies
- Gene Therapy
- Others
By Route of Administration
- Oral
- Parenteral
- Others
Atrial Fibrillation Pipeline Assessment Segmentation by Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase IV covers a major share of the total atrial fibrillation clinical trials. Phase IV holds 45.89%, demonstrating a strong presence of approved drugs that enhance treatment accessibility and market growth. Phase III follows with 29.45%, indicating promising late-stage developments. Phase II accounts for 14.38%, reflecting innovation in mid-stage trials. Phase I contributes 8.22%, while Early Phase I at 2.05% highlights emerging advancements. These progressions drive innovation and expand treatment options in the atrial fibrillation market.Atrial Fibrillation Pipeline Assessment Segmentation by Drug Classes
The drug molecule categories covered under the atrial fibrillation pipeline analysis include small molecules, monoclonal antibodies, anticoagulants, RNA-based therapies, gene therapy, and others. The atrial fibrillation report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for atrial fibrillation.Potassium channel blockers are emerging as a promising class in the atrial fibrillation pipeline. For instance, AP30663, a KCa2 channel inhibitor, has shown efficacy in animal models. A trial is evaluating its potential in patients with AF episodes lasting seven days or less, comparing intravenous doses of 3 or 5 mg/kg against a placebo.
Atrial Fibrillation Clinical Trials - Key Players
The report for the atrial fibrillation pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed atrial fibrillation therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in atrial fibrillation clinical trials:- Huya Bioscience International
- Thryv Therapeutics, Inc.
- Anthos Therapeutics, Inc.
- Daiichi Sankyo Korea Co., Ltd.
- Sahajanand Medical Technologies Limited
- Janssen Research & Development, LLC
- Bristol-Myers Squibb
- Medtronic
- Helios Cardio Inc.
- HK inno.N Corporation
Atrial Fibrillation - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for atrial fibrillation. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of atrial fibrillation drug candidates.Drug: HBI-3000
HBI-3000, an intravenous antiarrhythmic drug sponsored by Huyabio International, LLC, is being evaluated in a Phase II study for the conversion of recent-onset atrial fibrillation (AF). This two-stage study includes dose escalation followed by a placebo-controlled phase to assess safety, efficacy, and tolerability. Containing sulcardine, HBI-3000 aims to reduce life-threatening arrhythmias, addressing limitations of current AF treatments.Drug: THRV-1268
THRV-1268, sponsored by Thryv Therapeutics, Inc., is undergoing a Phase I study to assess its safety, tolerability, and pharmacokinetics in healthy adults. This novel SGK1 inhibitor targets pathways associated with arrhythmias, fibrosis, and heart failure. With an estimated enrollment of 74 participants, the study involves single and multiple ascending doses to evaluate QTc interval effects and food interactions.Reasons To Buy This Report
The Atrial Fibrillation Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for atrial fibrillation. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within atrial fibrillation pipeline insights.Key Questions Answered in the Atrial Fibrillation Pipeline Insight Report
- Which companies/institutions are leading the atrial fibrillation drug development?
- What is the efficacy and safety profile of atrial fibrillation pipeline drugs?
- Which company is leading the atrial fibrillation pipeline development activities?
- What is the current atrial fibrillation commercial assessment?
- What are the opportunities and challenges present in the atrial fibrillation pipeline landscape?
- What is the efficacy and safety profile of atrial fibrillation pipeline drugs?
- Which company is conducting major trials for atrial fibrillation drugs?
- Which companies/institutions are involved in atrial fibrillation collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in atrial fibrillation?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Atrial Fibrillation
4 Patient Profile: Atrial Fibrillation
5 Atrial Fibrillation: Epidemiology Snapshot
6 Atrial Fibrillation: Market Dynamics
7 Atrial Fibrillation: Key Facts Covered
8 Atrial Fibrillation, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Atrial Fibrillation Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Atrial Fibrillation Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Atrial Fibrillation Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Atrial Fibrillation Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Atrial Fibrillation, Key Drug Pipeline Companies
